Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Ovarian Neoplasms 2Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Hereditary Breast and Ovarian Cancer Syndrome 1Fanconi Anemia 1Central Nervous System Neoplasms 1Breast Neoplasms 1

Interventions

fludarabine phosphate 3Antilymphocyte Serum 3Cyclophosphamide 2AP 1903 reagent 2thymoglobulin 1sargramostim 1prexasertib 1fludarabine 1Whole-Body Irradiation 1Tacrolimus 1SRA737 1Quercetin 1Peripheral Blood Stem Cell Transplantation 1Mycophenolic Acid 1Methylprednisolone 1Melphalan 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Dietary Supplements 1Cord Blood Stem Cell Transplantation 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Fanconi Anemia × prexasertib × Clear all
NCT02873975 2022-10-21

A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency

Dana-Farber Cancer Institute

Phase 2 Completed
27 enrolled 13 charts
Classical hematology

Fanconi Anemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡